XTALPI (02228) announced that its industry-leading AI-driven molecular discovery platform has successfully developed and validated two innovative topical ingredients—small molecule Remeanagen™ (XTP-118) and peptide AquaKine™ (XTP-016)—which combine hair loss prevention and regrowth effects.

The synergistic formulation of these "Twin Star" molecules has demonstrated superior efficacy, safety, and faster onset in human clinical trials compared to existing alternatives. Both molecules have obtained INCI (International Nomenclature of Cosmetic Ingredients) registration in the U.S., while their combined product, Groland, has secured FDA cosmetic filing approval.

This milestone marks XTALPI’s official entry into the high-potential consumer health market. Moving forward, the company will continue advancing drug R&D for critical diseases while also creating consumer-grade molecular products to enhance daily life.

XTALPI’s new mission statement reflects this dual focus: "Let AI flow into every new drug" and "Let AI molecules enrich everyone’s quality of life." The AI platform now bridges life-saving pharmaceutical innovations with safe, effective consumer solutions.